Business
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
MARSEILLE, France, May 13, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2025.
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/35309ff99f9439b0a8e94d4810e8e069"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NBnYDwqiVg7It.PtuXAphw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/35309ff99f9439b0a8e94d4810e8e069","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xkeX4lBNb.sSc8RONOpfhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/35309ff99f9439b0a8e94d4810e8e069","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting","length":184,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome; long term follow up data from TELLOMAK Phase 2 to be presented at ASCO Annual Meeting 2025","length":192,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position of €72.5 million1 as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid 2026","length":133,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET","length":65,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":731,"olType":false},{"type":"text","content":"MARSEILLE, France, May 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2025.","length":189,"tagName":"p"},{"type":"text","content":""The first quarter of 2025 was marked by ...